The global pseudomonas aeruginosa treatment market is expected to cross USD 7.5 billion by 2027. It can achieve growth at ra CAGR of 7% over the forecast peiod. It stood at USD 1 billion in 2018. Development of suitable vaccines for fighting non-communicable and hereditary diseases is likely to drive the market demand. For instance, antibody tests for testing the strength of pseudomonas aeruginosa in cystic fibrosis can used to determine the strength of vaccines. Huge prevalence of bacterial infections and its causal mortality rate can drive the demand for antibiotic drugs. For instance, the World Health Organization (WHO) has developed a top priority pathogen list which includes the soil bacteria.
Focus of pharmaceutical companies in the development of drugs for treatment of pseudomonas aeruginosa and approvals by federal agencies of nations can bolster the market demand. Rise of health-acquired infections (HAIs) caused by soil bacteria can drive the demand in the global pseudomonas aeruginosa treatment market.
Bayer AG, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Co., Lupin Pharmaceuticals, Inc., Novartis AG, AmpliPhi Biosciences Corp, Pfizer, Inc., AstraZeneca, Janssen Pharmaceuticals, Inc., Gilead Sciences Inc., Merck Co., Inc., Allergan Plc, Aradigm Corp, PARI Medical Holding GmbH, and Humanigen Inc are key players of the global pseudomonas aeruginosa treatment market.
Segmentation
The global pseudomonas aeruginosa treatment market is segmented by medication, route of administration, and distribution channel.
- By medication, it is divided into monotherapy and combination therapy.
- By route of administration, it is segmented into intravenous, oral, and nasal.
- By distribution channel, it is segmented into online pharmacies, retail pharmacies, and hospital pharmacies.
Regional Analysis
The Americas, Asia Pacific (APAC), Europe, and the Middle East Africa (MEA) are regions considered for the global pseudomonas aeruginosa market.
The Americas is the largest regional market and touted to dominate till the end of the forecast period. An increasing number of chronic diseases, eye infection, urinary infection, bone and joint infections, and other diseases due to soil bacteria are likely to drive the growth of the market during the assessment period. The Centers for Disease Control (CDC) has estimated that in American hospitals alone, HAIs caused 1.7 million infections and 99,000 deaths annually.
Europe is driven by the large number of healthcare companies providing diagnostic and treatment solutions for Pseudomonas Aeruginosa infections.
APAC is the fastest-growing regional market for Pseudomonas Aeruginosa treatment. The huge population, the growing geriatric population, and huge numbers of low immune patients are prone to infections by Pseudomonas Aeruginosa can drive the growth of the market.
The developing healthcare infrastructure and growing treatment options for Pseudomonas Aeruginosa infections in the MEA region can boost the market demand significantly.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
Market Research Future (MRFR) team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
